IDENTIFY-HF Study, Version 1.0

  • Research type

    Research Study

  • Full title

    IDENTIFY-HF The Heart Failure with Preserved Ejection Fraction (HFPEF) Pathophysiology Study Does ageing coupled with vascular effects of comorbidities lead to HFPEF? An in-depth understanding from a tertiary centre

  • IRAS ID

    216153

  • Contact name

    Prithwish Banerjee

  • Contact email

    prithwish.banerjee@uhcw.nhs.uk

  • Sponsor organisation

    University Hospitals Coventry & Warwickshire NHS Trust

  • Duration of Study in the UK

    1 years, 6 months, 8 days

  • Research summary

    Heart failure (HF) is a major growing public health concern and Heart failure with preserved ejection fraction (HFPEF) forms about 50% of the total heart failure burden. The prognosis of HFPEF is similar to systolic heart failure, now referred to as heart failure with reduced ejection fraction (HFREF), with an estimated 5-year mortality of around 50%. This is worrying as no treatments that influence outcome in HFPEF have so far been found, despite a reasonable amount of research. Furthermore, the exact pathophysiologic processes that cause HFPEF are not completely understood.

    In this single centre (Coventry), observational, non-interventional study, we investigate the hypothesis that arterial stiffness increases with comorbidities, in addition to ageing, resulting in the HFPEF syndrome. In order to investigate this, several groups will be compared all ≥ 70 years of age. The study participants enrolled will comprise of five groups (21 patients in each group) including a parallel group (11 patients). Hence, 95 patients in total will be enrolled and the groups are as follows:

    A) Normal healthy volunteers without major disease(such as hypertension, diabetes or renal failure)
    B) Patients with hypertension without diabetes mellitus
    C) Patients with hypertension AND diabetes mellitus
    D) Patients with HFPEF.
    E) Parallel group will be a HFREF group.

    Our primary objective is to demonstrate if there is increasing arterial resistance from group A to group D and a significant difference in arterial resistance between group D and E. The study involves a single visit in each participant with several investigations being undertaken(Pulse Wave Velocity, blood test, transthoracic echocardiography, cardiopulmonary exercise test and a 6-minute walk test).

    We hope our study will shed light on the HFPEF pathophysiology, which
    will enable adequate, targeted evidence-based treatment to be given to this large patient group in order to reduce mortality and costly hospital admissions.

  • REC name

    West Midlands - Black Country Research Ethics Committee

  • REC reference

    17/WM/0039

  • Date of REC Opinion

    7 Feb 2017

  • REC opinion

    Favourable Opinion